Merck Drug Improves Cholesterol Without Safety Risk

An experimental drug from Merck & Co. raised levels of good cholesterol, slashed bad cholesterol and may have helped patients avert heart complications, without the safety risks that prompted Pfizer Inc. to abandon a similar product four years ago.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.